Hauptseite > Publikationsdatenbank > The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles? > print

001     916872
005     20231027114351.0
024 7 _ |a 10.1002/mds.29266
|2 doi
024 7 _ |a 0885-3185
|2 ISSN
024 7 _ |a 1531-8257
|2 ISSN
024 7 _ |a 2128/33842
|2 Handle
024 7 _ |a 36345092
|2 pmid
024 7 _ |a WOS:000879614200001
|2 WOS
037 _ _ |a FZJ-2023-00164
082 _ _ |a 610
100 1 _ |a Hoenig, Merle C.
|0 P:(DE-Juel1)178642
|b 0
|e Corresponding author
245 _ _ |a The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?
260 _ _ |a New York, NY
|c 2023
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1675167770_18375
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Across neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease (AD), a disparity between the clinical expression and the extent of pathophysiological burden has been observed. This has fueled the establishment of resilience concepts such as cognitive reserve (CR) and brain reserve (BR) at the beginning of this millennium.1 Since the introduction of these concepts, a plethora of studies have aimed at identifying mechanisms predominantly associated with the mitigation of cognitive decline despite neurodegenerative changes associated with multiple sclerosis, dementia, or healthy aging (ie, resilience).2, 3 In comparison, resilience mechanisms in PD have received far less attention even though they seem equally important given the clinical heterogeneity and long prodromal phase. With the emerging concept of motor reserve (MR), new avenues have opened up focusing on potential neuronal processes providing resilience (ie, relative preservation of motor function) in PD, which can potentially be harnessed for interventional therapies. Importantly, this requires a common understanding of the principles of how to assess resilience in observational studies and how to quantify its underlying mechanisms. Given the head start in identifying pitfalls and precisely delineating the concept of resilience in the AD field, the opportunity lies at hand to benefit from this knowledge for investigations of MR in PD.
536 _ _ |a 5252 - Brain Dysfunction and Plasticity (POF4-525)
|0 G:(DE-HGF)POF4-5252
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Dzialas, Verena
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Drzezga, Alexander
|0 P:(DE-Juel1)177611
|b 2
700 1 _ |a van Eimeren, Thilo
|0 P:(DE-Juel1)169110
|b 3
773 _ _ |a 10.1002/mds.29266
|g p. mds.29266
|0 PERI:(DE-600)2041249-6
|n 1
|p 16-20
|t Movement disorders
|v 38
|y 2023
|x 0885-3185
856 4 _ |u https://juser.fz-juelich.de/record/916872/files/Movement%20Disorders%20-%202022%20-%20Hoenig%20-%20The%20Concept%20of%20Motor%20Reserve%20in%20Parkinson%20s%20Disease%20New%20Wine%20in%20Old%20Bottles.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:916872
|p openaire
|p open_access
|p OpenAPC_DEAL
|p driver
|p VDB
|p openCost
|p dnbdelivery
|q OpenAPC
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)178642
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)177611
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5252
|x 0
914 1 _ |y 2023
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a DEAL: Wiley 2019
|2 APC
|0 PC:(DE-HGF)0120
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-11
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2022-11-11
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-24
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOVEMENT DISORD : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-24
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOVEMENT DISORD : 2022
|d 2023-10-24
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-2-20090406
|k INM-2
|l Molekulare Organisation des Gehirns
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-2-20090406
980 _ _ |a APC
980 1 _ |a APC
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21